Fulcrum Therapeutics (FULC) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fulcrum Therapeutics is launching an open-label extension study called “An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of Pociredir in Participants With Sickle Cell Disease (SCD) Who Have Participated in a Pociredir Study.” The goal is to track long-term safety and tolerability in sickle cell patients who previously showed benefit on pociredir, making this an important step for building a durable data story.
The treatment is pociredir, an oral drug also known as FTX-6058, taken once daily as capsules. It is designed to help people with sickle cell disease by offering a long-term therapy option for those who already responded well in an earlier study.
This is an interventional Phase 2 study that uses a single group design with no randomization and no placebo arm. Everyone in the trial receives pociredir, and there is no blinding, so both doctors and patients know they are on active treatment, with the main aim being treatment safety over time.
Participants can receive pociredir for up to 48 months, which gives management a long observation window on chronic use. The trial is not yet recruiting, with first submission on 28 January 2026 and the latest update filed on 18 March 2026, signaling active planning and regulatory engagement ahead of enrollment.
For investors, the update confirms Fulcrum’s commitment to building a long-term safety package around pociredir, a key requirement for any potential commercial launch in sickle cell disease. Positive safety and durability data could support sentiment on FULC versus other sickle cell players, though timelines remain extended and competition from larger firms in gene therapies and other drugs stays intense.
This study is currently in the setup phase and remains active in planning, with further details and ongoing updates available on the ClinicalTrials portal.
To learn more about FULC’s potential, visit the Fulcrum Therapeutics drug pipeline page.